top of page
covid sars1.jpg

PAXLOVID and COVID-19

Educational Resources - Pfizer Approved Medicines and Therapeutic Areas of Interest

New Classes added every month

Anchor 1
Educational Resources
PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)

PDF DOCUMENTS

EDUCATIONAL VIDEOS

INTERACTIVE WEB PAGES

COVID-19

EDUCATIONAL DOCUMENTS

Paxlovid PDFs
Paxlovid MOVs
Paxlovid HTMs
Covid iPDFs

PAXLOVID™ has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

bottom of page